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Abstract
Purpose The purpose of this study is to establish the
prevalence of potentially inappropriate prescribing (PIP)
in middle-aged adults (45–64 years) in two populations
with differing socio-economic profiles, and to investigate
factors associated with PIP, using the PROMPT (PRe-
scribing Optimally in Middle-aged People’s Treatments)
criteria.
Methods A retrospective cross-sectional study was conducted
using 2012 data from the Enhanced Prescribing Database
(EPD), covering the full population in Northern Ireland and
the Health Services Executive Primary Care Reimbursement
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Service (HSE-PCRS) database, covering the most
socio-economically deprived third of the population in this
age group in the Republic of Ireland. The prevalence for each
PROMPT criterion and overall prevalence of PIP were calcu-
lated. Logistic regression was used to investigate the associa-
tion between PIP and gender, age group and polypharmacy.
Results This study included 441,925 patients from the EPD
and 309,748 patients from the HSE-PCRS database.
Polypharmacy was common in both datasets (46.7 % in the
HSE-PCRS and 20.3 % in the EPD). The prevalence of PIP
was 42.9 % (95%CI 42.7, 43.1) in the HSE-PCRS and 21.1 %
(95%CI 21.0, 21.2) in the EPD. Age group, female gender and
polypharmacy were significantly associated with PIP in both
populations (p < 0.05) and polypharmacy had the strongest
association.
Conclusions PIP is common amongst middle-aged people
with the risk of PIP increasing with polypharmacy. Differ-
ences in the prevalence of polypharmacy and PIP between
the two populations may relate to heterogeneity in healthcare
services and different socio-economic profiles, with higher
rates of multimorbidity and associated polypharmacy in more
deprived groups.
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Abbreviations
ATC Anatomical therapeutic chemical
BNF British national formulary
BSO Business services organisation
CIs Confidence intervals
DDD Defined daily doses
EPD Enhanced prescribing database
GP General practitioner
HSC Health and social care
HSE-
PCRS
Health services executive primary care reim-
bursement service
HCPs Healthcare professionals
NHS National health service
NSAID Non-steroidal anti-inflammatory drug
ORs Odds ratios
PIP Potentially inappropriate prescribing
PROMPT Prescribing optimally in middle-aged people’s
treatments
PPIs Proton pump inhibitors
TCAs Tricyclic antidepressants
Introduction
As prescribing guidelines generally focus on single diseases
[1], the increasing prevalence of patients with two or more
chronic conditions, or multimorbidity [2], creates challenges
in determining the appropriateness of prescribing. Tradition-
ally, the focus of potentially inappropriate prescribing (PIP)
has been on older people (routinely defined as aged 65 years
and over) due to the complexity of prescribing for patients in
this age group, including changes in pharmacokinetics and
pharmacodynamics [3], and a high prevalence of
multimorbidity (82% aged ≥85 years; 65% aged 65–84 years)
[2]. Multimorbidity presents risks to patients including poor
quality of life and increased healthcare services utilisation [4],
and is associated with the use of multiple medications, or
polypharmacy, which may increase the risk of adverse drug
events or hospitalisation [5]. However, polypharmacy may be
appropriate in the treatment of many conditions [6], and the
challenge for prescribers is to determine the appropriateness of
prescribing in the context of multiple conditions and medica-
tions while prioritising therapeutic management when there is
a conflict between medications and/or illnesses. PIP may be
evaluated using explicit (criterion-based) or implicit
(judgement-based) tools which have been developed to opti-
mise prescribing [7–13]. Despite approximately one third of
middle-aged people (routinely defined as aged 45–64 years)
living with multiple conditions, there has been a paucity of
research in PIP in middle-aged adults [2]. PROMPT (PRe-
scribing Optimally in Middle-aged People’s Treatments) rep-
resents a set of 22 explicit prescribing criteria, organised ac-
cording to physiological system, which have been developed
specifically for middle-aged adults [8]. This set of criteria may
be applied to administrative datasets, or drug lists alone (i.e. in
the absence of clinical information), to determine the preva-
lence of PIP in middle-aged people [8]. The criteria are similar
to the Screening Tool for Older Persons’ Prescription
(STOPP) [10] in mainly specifying circumstances in which a
medicine may be inappropriate (co-morbidities, dosage,
duration of use) rather than stating drugs to avoid in all cases
as is more common in the Beers criteria [9].
The aim of this study is to establish the prevalence of PIP
in middle-aged adults defined using the PROMPT criteria
in two populations (Northern Ireland and the Republic of
Ireland) with differing socio-economic profiles, and inves-
tigate any association between PIP and polypharmacy, gen-
der and age group.
584 Eur J Clin Pharmacol (2016) 72:583–591
3 School of Pharmacy, Royal College of Surgeons in Ireland, 123 St
Stephen’s Green, Dublin 2, Ireland
4 Department of Pharmacology & Therapeutics, Trinity Centre for
Health Sciences, St. James’s Hospital, Dublin 8, Ireland
5 Economic and Social Research Institute, Whitaker Square, Sir John
Roberson’s Quay, Dublin 2, Ireland
6 Department of Geriatric and Stroke Medicine, Royal College of
Surgeons in Ireland, 123 St Stephen’s Green, Dublin 2, Ireland
Methods
Study design and setting
This is a retrospective cross-sectional study using data from the
Enhanced Prescribing Database (EPD) in Northern Ireland and
the Health Services Executive Primary Care Reimbursement
Service (HSE-PCRS) database in the Republic of Ireland.
The Enhanced Prescribing Database
The Enhanced Prescribing Database (EPD), first established in
2008, is a population-based dataset which collates information
on computer-generated prescriptions issued in general practice
and subsequently dispensed in a community pharmacy in North-
ern Ireland. Prescriptions generated in general practices contain
two-dimensional (2-D) barcodes which hold all relevant infor-
mation on the prescription for example, patient details [name,
address, age, date of birth and Health and Social Care (HSC)
number], prescriber details (general practice and prescriber) and
medication information [medication(s) prescribed including
dose, strength and quantity and date of issue]. Prescriptions dis-
pensed by community pharmacies are forwarded to the data
custodians, the Business Services Organisation (BSO), each
month for reimbursement where the barcodes are scanned, with
data from approximately 85–90 % of all prescriptions added to
the EPD database [14]. Since 2010, all medicines available in
Northern Ireland via the National Health Service (NHS) have
been free at the point of dispensing. According to Census data
for Northern Ireland, there were approximately 442,000 individ-
uals in Northern Ireland aged between 45 and 64 years (males,
49 %; females, 51 %) in 2011 [15].
The Health Services Executive Primary Care
Reimbursement Service
The Health Services Executive Primary Care Reimbursement
Service (HSE-PCRS) database records pharmacy claims for
dispensed medicines that were prescribed to patients by their
general practitioner (GP). Drug information on strength, quan-
tity dispensed, dosage form and defined daily doses (DDD) is
also included. Some patient demographic data are recorded
such as age, gender and region. The General Medical Services
(GMS) scheme is a form of public health cover that provides
free health services including prescription medicines to eligi-
ble persons in Ireland (although a small monthly co-payment
of €0.50 per medication was introduced in October 2010).
Eligibility for the scheme is determined by means testing
and a common family/household income threshold applies
to people aged <70 years, with a higher income threshold
for older individuals. Approximately 40.4 % of the total pop-
ulation of the Republic of Ireland were eligible for the scheme
in 2012, while 348,025 of 1,054,300 individuals aged 45–
64 years in the national population (33 %) were eligible [16,
17]. Due to the eligibility criteria, the GMS scheme
over-represents socio-economically deprived individuals, par-
ticularly those aged <70 years.
Study population
For each dataset, the study population contained all individ-
uals aged 45 years or older on 1st January 2012. Prescribing
data were included until 31st December 2012, or until the
individual’s 65th birthday (month), whichever came first. In
Northern Ireland, the study population included all patients
who remained registered with a general practice in Northern
Ireland during the study period. Patients who migrated into or
from Northern Ireland, or died during the study period, were
excluded from the cohort. Furthermore, only patients regis-
tered with general practices with a scan rate greater or equal
to 80 % [i.e. (ratio of readable barcodes produced by the gen-
eral practice in 1 month/total number of dispensed prescrip-
tions from the general practice in 1 month)*100] were includ-
ed in the study population. In the Republic of Ireland, the
study population included all individuals eligible for the
HSE-PCRS GMS scheme, who were dispensed a prescription
during the study period. The research team had no access to
patient identifiable information in either dataset. Ethical ap-
proval for the use of EPD data was obtained from the NHS
Research Ethics Committees (REC), under proportionate re-
view (REC reference 14/SW/0038). Permission was given by
the data controller of the HSE-PCRS database for use if data
were anonymised and analysed so that no subgroup contained
fewer than five individuals, and therefore, it was not necessary
to seek specific ethical approval for this analysis.
Data extraction
Data were extracted for the study period between 1st January
2012 and 31st December 2012. In the EPD dataset, medica-
tions were extracted using British National Formulary (BNF)
codes, whereas in the HSE-PCRS database, World Health
Organisation (WHO) Anatomical Therapeutic Chemical
(ATC) codes were used. Dispensing data prior to the study
start date were required to determine previous medication his-
tory for some criteria [for example, Tricyclic antidepressants
(TCAs) (e.g. amitriptyline, nortriptyline) should not be used
as first-line in treatment of depression]. Therefore, a lead-in
period of 3 months was required for all patients (data were
extracted between 1st October 2011 and 31st December
2012). A description of the analytical approach used to apply
various criteria is included in Supplementary file 1.
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Outcomes
Patients were categorised as having received, or not having re-
ceived, any of the PIPs listed in the 22 criteria [8]. The primary
outcome was the overall prevalence of PIP, defined as having
any one of the 22 PROMPT criteria. Secondary outcomes were
the prevalence of individual PROMPT criteria, and the associa-
tion between presence of any PIP (binary variable),
polypharmacy and gender (male/female). These factors were
assessed as they have been shown to be associated with PIP in
older people in previous research [18]. The association between
increasing age groups (45–49, 50–54, 55–59 and 60–64 years)
was also investigated as a secondary outcome. Polypharmacy
was assessed by calculating the number of different medication
classes which were dispensed at least three times to each indi-
vidual during the study period. Medication classes were defined
byBNF sections in the EPD and five-character ATC codes in the
HSE-PCRS. Although there is no universally accepted defini-
tion of the term polypharmacy, the conventional definition of
four or more medications was used in this study [19].
Statistical analysis
A percentage estimate with 95 % confidence intervals (CI) for
the overall prevalence of PIP for all the PROMPT criteria and
the prevalence of PIP defined by each individual PROMPT
criterion were calculated. These estimates represent the num-
ber of individuals exposed to a PIP as a proportion of all
individuals in each dataset (i.e. all those from the included
populations who were dispensed a prescription during
2012). Adjusted logistic regression analyses were used to cal-
culate odds ratios (OR) and 95 % CI to investigate any asso-
ciation between any PIP and polypharmacy, gender and age
groups. Data extraction from the EPD was performed in
MySQL and data were incorporated into STATA version
11.0 [StataCorp 2005, College Station, TX, USA] for analy-
ses. Analyses on the HSE-PCRS database were performed
using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Descriptive statistics
This study included 441,925 patients from the EPD and 309,
748 patients from the HSE-PCRS database. Descriptive statis-
tics for these two populations are shown in Table 1.
Polypharmacy levels were high, with 46.7 and 20.3 % of
individuals receiving ≥4 different drugs classes in the
HSE-PCRS database and EPD database, respectively.
Prevalence of overall PIP and criterion-specific PIP
The overall prevalence of PIP was 42.9 % (95 % CI 42.7, 43.1)
in the Republic of Ireland and 21.1 % (95 % CI 21.0, 21.2) in
Northern Ireland (Table 2). Prevalence estimates were calculated
for each individual PROMPT criterion (and are included in
Supplementary file 2) and a number of criteria were common
in both populations (Table 3). Strong opioids without
co-prescription of an osmotic or stimulant laxative was the most
prevalent instance of PIP in the EPD (prevalence 6.9%), follow-
ed by prescription of proton pump inhibitors (PPIs) above main-
tenance dosage for greater than 8 weeks (6.9 %). In the HSE-
PCRS database, these criteria were the second and first most
common criteria, found in 13.9 and 17.7 % of individuals re-
spectively. The next most prevalent PIP was the same in both
populations, with a benzodiazepine being prescribed long-term
(for >4 weeks) to 2.9 % of individuals in the EPD and 8.5 % of
those in the HSE-PCRS database. The long-term use of non-
benzodiazepine hypnotics (Z-drugs) was fourth (8.3%) and fifth
(2.5 %) most prevalent in the HSE-PCRS and EPD populations,
respectively. The other most common PIP differed between the
two populations, with first generation anti-histamines being pre-
scribed for greater than 7 days for 2.5 % of EPD patients and
only 0.5 % of HSE-PCRS patients, and non-steroidal anti-in-
flammatory drugs (NSAIDs) being prescribed for greater than
3months to 5.0% of individuals in theHSE-PCRS database and
1.4 % of those in the EPD.
Analysis of duplication of drug classes within the same
month in the EPD found the prevalence was 5.7 % (95 % CI
5.6, 5.8) and opioids, benzodiazepines and NSAIDs were the
most commonly implicated drugs (Table 2). The prevalence of
duplication in the HSE-PCRS database was 11.3 % (95 % CI
11.2, 11.4) and opioids were most likely to be duplicated,
Table 1 Participant demographics
EPDa (N = 441,925) HSE-PCRSb (N = 309,748)
n % n %
Female 218,498 49.4 165,588 53.5
Polypharmacy 89,631 20.3 144,485 46.7
Age group
45–49 years 125,979 28.5 67,424 21.8
50–54 years 114,585 25.9 74,298 24.0
55–59 years 97,740 22.1 73,440 23.7
60–64 years 103,621 23.5 94,586 30.5
Mean SD Mean SD
Age (years) 54.1 6.01 55.3 5.84
a Enhanced Prescribing Database, covering the full middle-aged popula-
tion of Northern Ireland
bHealth Service Executive Primary Care Reimbursement database, cov-
ering the most socioeconomically deprived third of the middle-aged pop-
ulation of the Republic of Ireland
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followed by NSAIDs and benzodiazepines. Duplication of stim-
ulant laxatives occurred in 0.1 % of the EPD population (642
individuals); however, there were no instances of this in the
HSE-PCRS database.
Association of PIP with polypharmacy, gender and age
Adjusted logistic regression analysis was performed in each
population to determine factors associated with having PIP
(Table 4). Age group, gender and polypharmacy were all sig-
nificantly associated with having PIP in the univariate logistic
regression in both populations (p < 0.05) and odds ratios were
of similar orders of magnitude. After controlling for age group
and gender, the adjusted odds ratio (OR) for having PIP in
those with polypharmacy compared to no polypharmacy was
11.99 (95 % CI 11.78, 12.20) in the EPD population and 7.96
(95 % CI 7.83, 8.09) in the HSE-PCRS population. Female
gender was also associated with increased odds of having a
PIP (adjusted OR 1.51 and 1.12 in the EPD and HSE-PCRS
database, respectively). In the univariate analysis, odds of PIP
increased with each 5 year increase in age group; however,
once polypharmacy and gender were adjusted for, odds were
higher and approximately equal across the three older age
groups compared to the reference group of 45–49 years.
Discussion
Overall prevalence of PIP
Using the PROMPT criteria, this study has shown that PIP is
common among middle-aged people (42.9 % in the HSE-
PCRS database in the Republic of Ireland and 21.1 % in the
EPD in Northern Ireland). The difference in the overall
Table 2 Summary PIP
prevalence estimates EPD
a HSE-PCRSb
n % (95 % CI) n % (95 % CI)
Overall PIP prevalence 93,319 21.1 (21.0, 21.2) 132,813 42.9 (42.7, 43.1)
Number of PIPs
1 PIP 55,960 12.7 (12.6, 12.8) 71,462 23.1 (22.9, 23.2)
2 PIPs 22,125 5.0 (4.9, 5.1) 33,403 10.8 (10.7, 10.9)
≥3 PIPs 15,234 3.4 (3.4, 3.5) 27,948 9.0 (8.9, 9.1)
Duplicate drug class prevalence 25,209 5.7 (5.6, 5.8) 35,104 11.3 (11.2, 11.4)
a Enhanced Prescribing Database, covering the full middle-aged population of Northern Ireland
bHealth Service Executive Primary Care Reimbursement database, covering the most socioeconomically de-
prived third of the middle-aged population of the Republic of Ireland
Table 3 Most common instances of PIP and duplication of drug classes
EPDa HSE-PCRSb
PROMPT criterion n Rank % (95 % CI) n Rank % (95 % CI)
Strong opioids should not be prescribed without the
co-prescribing of at least one osmotic or stimulant laxative
30,679 1st 6.9 (6.9, 7.0) 43,041 2nd 13.9 (13.8, 14.0)
Proton pump inhibitors (PPIs) should not be prescribed at doses
above the recommended maintenance dosage for >8 weeks.
30,367 2nd 6.9 (6.8, 6.9) 54,762 1st 17.7 (17.5, 17.8)
Benzodiazepines should not be used for >4 weeks 12,630 3rd 2.9 (2.8, 2.9) 26,395 3rd 8.5 (8.4, 8.6)
First-generation antihistamines should not be used as first-line
agents for >7 days.
11,098 4th 2.5 (2.5, 2.6) 1556 11th 0.5 (0.5, 0.5)
Non-benzodiazepine hypnotics should not be used for >4 weeks 10,875 5th 2.5 (2.4, 2.5) 25,611 4th 8.3 (8.2, 8.4)
Non-steroidal anti-inflammatory drugs (NSAIDs) should not
be used for >3 months
6284 7th 1.4 (1.4, 1.5) 15,488 5th 5.0 (4.9, 5.1)
Duplicate drug classes
Opioids 16,356 1st 3.7 (3.6, 3.8) 12,523 1st 4.0 (4.0, 4.1)
Benzodiazepines 5089 2nd 1.2 (1.1, 1.2) 10,539 3rd 3.4 (3.3, 3.5)
NSAIDs 1656 3rd 0.4 (0.4, 0.4) 11,653 2nd 3.8 (3.7, 3.8)
a Enhanced Prescribing Database, covering the full middle-aged population of Northern Ireland
bHealth Service Executive Primary Care Reimbursement database, covering themost socioeconomically deprived third of themiddle-aged population of
the Republic of Ireland
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prevalence of PIP between these two neighbouring popula-
tions may be explained by a number of factors including dif-
ferences in the socio-economic profile of the included popu-
lations and heterogeneity in healthcare services between the
North and Republic of Ireland. The included populations are
not directly comparable, but this work allowed us to explore
the prevalence of PIP across two populations with different
healthcare systems. In Northern Ireland, computer-generated
prescriptions issued by GPs are free of charge, and therefore,
the dataset is representative of the middle-aged national pop-
ulation. In the Republic of Ireland, the HSE-PCRS cohort
contained middle-aged people with an income level below
the eligibility threshold for the GMS scheme. Therefore, the
HSE-PCRS cohort represents a more socio-economically de-
prived population than in the EPD dataset.
If the higher prevalence of PIP observed in the HSE-PCRS
database is related to socio-economic deprivation, this rela-
tionship could be driven by a number of factors. Lower
socio-economic status and health literacy can have an adverse
effect on the quality of patient-doctor communication and the
degree of patient involvement in shared decision making,
which may potentially impact on the quality of care and the
risk of PIP [20, 21]. Poorer health has been reported in socio-
economically deprived areas [22], with an increased preva-
lence of long-term conditions including depression, anxiety,
pain and coronary heart disease [23]. A large cohort study
using primary care data for nearly 300,000 patients aged
≥30 years from the UK Clinical Practice Research Datalink
showed that those in the most deprived quintile had the
highest proportion of multiple morbidity and deaths [24]. Fur-
thermore, a recent large cross-sectional study examining over
1.7 million patients (all ages) using a primary care database in
Scotland showed that people living in the most deprived areas
tended to develop multimorbidity at a younger age compared
to those in affluent areas [2]. Polypharmacy has consistently
been shown to be the strongest predictor of PIP, and socio-
economic status has been linked to the number of regular
medicines prescribed. A large cross-sectional analysis of Scot-
tish primary care patients aged 20 years and over demonstrat-
ed a linear relationship between deprivation and number of
regular medicines, independent of age group and number of
clinical conditions [25]. A nationally representative study on
ageing in the Republic of Ireland found a larger difference in
prevalence of polypharmacy across levels of educational at-
tainment in people aged 50–64 years compared to those aged
65 and over, indicating socio-economic status may be a more
important predictor of polypharmacy in middle-aged individ-
uals than in older people [26]. Deprivation has also been
linked with other forms of sub-optimal prescribing, such as
higher levels of interacting drugs and lower levels of second-
ary prevention in older people [27] and high-risk prescribing
in adults across all age groups [28].
Although the different socio-economic profiles of the two
study populations was likely the biggest contributing factor to
differences in PIP prevalence, there may be other cultural
factors (potentially influencing the behaviour of the public
and doctors) or systems factors (such as government regula-
tion) which shape prescribing practice and give rise to differ-
ences between the two jurisdictions [29]. For example, differ-
ences between Northern Ireland and the Republic of Ireland in
how the healthcare systems are structured may explain the
disparity in PIP prevalence to some degree. However, a pre-
vious comparative study found larger differences in the prev-
alence of PIP between the UK and Northern Ireland, which
have similar healthcare systems, than between Northern Ire-
land and the Republic of Ireland, which have similar popula-
tion demographics, suggesting the latter may be a more im-
portant contributory factor [18].
Most common instances of PIP
The most common instances of PIP were the use of strong
opioids without co-prescription of an osmotic or stimulant
laxative, prescription of PPIs above the maintenance dosage
Table 4 Logistic regression analyses for having any PIP criteria by dataset
Unadjusted OR (95 % CI) Adjusted OR (95 % CI)
EPDa HSE-PCRSb EPDa HSE-PCRSb
Polypharmacy (vs none) 12.11 (11.90, 12.31) 8.05 (7.92, 8.18) 11.99 (11.78, 12.20) 7.96 (7.83, 8.09)
Female (vs male) 1.51 (1.48, 1.53) 1.15 (1.13, 1.17) 1.51 (1.48, 1.53) 1.12 (1.10, 1.14)
Age group (years)
45–49 (reference) 1 1 1 1
50–54 1.31 (1.28, 1.34) 1.31 (1.28, 1.34) 1.08 (1.05, 1.10) 1.08 (1.04, 1.09)
55–59 1.59 (1.55, 1.62) 1.61 (1.58, 1.64) 1.08 (1.06, 1.11) 1.09 (1.07, 1.18)
60–64 1.85 (1.82, 1.89) 1.79 (1.75, 1.83) 1.07 (1.04, 1.09) 1.07 (1.04, 1.09)
a Enhanced Prescribing Database, covering the full middle-aged population of Northern Ireland
bHealth Service Executive Primary Care Reimbursement database, covering themost socioeconomically deprived third of themiddle-aged population of
the Republic of Ireland
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for greater than 8 weeks and the use of benzodiazepines for
greater than 1 month. These findings are consistent with pre-
vious studies which reported PIP in the older population. A
retrospective cross-sectional study, which used data from the
EPD (between 2009 and 2010), applied a subset of 28 criteria
from STOPP [30] to more than 166,000 patients aged
≥70 years and reported similar trends in PIP among the older
population (use of PPIs at a maximum therapeutic dose for
greater than 8 weeks, NSAIDs for greater than 3 months and
benzodiazepines for greater than 1 month being the most prev-
alent) [14]. Similarly, a retrospective national population
study using the HSE-PCRS (in 2007), applied 30 STOPP
criteria to dispensing records for over 338,000 patients aged
≥70 years with the same PIP criteria occurring most
commonly [31].
Association between PIP, polypharmacy, gender and age
In our study populations, age, gender and polypharmacy were
all significantly associated with PIP. There is some evidence
of an association between female gender and increased PIP in
older people, but this has not been reported consistently [14,
31]. Rates of multimorbidity have been shown to be higher in
females than males, which may result in the use of a higher
numbers of medications [2]. After controlling for age group
and gender, the risk of PIP increased with polypharmacy,
identifying polypharmacy as the principal determinant of
PIP. This strong association between PIP (as measured by
PROMPT) and polypharmacy in this study has also been
shown among the older population [14, 31].
Similarities in PIP between middle-aged and older people
may suggest that interventions aimed at improving inappro-
priate prescribing could include both age groups. As a number
of the most prevalent PIP criteria related to long-term use,
ensuring new prescriptions are reviewed after suitable inter-
vals and discontinued where appropriate may help to address
these prescribing issues. Thus far, studies aimed at improving
appropriate polypharmacy in older patients have shown some
evidence of a reduction in PIP, but any improvement in clin-
ically significant outcomes, such as hospital admissions,
medication-related problems and patients’ overall quality of
life remains unclear [19]. Future studies investigating
healthcare outcomes may help inform interventions to im-
prove prescribing practices in these age groups, particularly
in females and the most socio-economically deprived popula-
tions where the risk of PIP is elevated. By targeting the ageing
population of the future (i.e. the middle-aged), this is a group
which will be the focus for health provision in the future.
Strengths and limitations of this study
This large observational study has several key strengths. First-
ly, the PROMPT criteria have been developed for use in
prescribing or dispensing datasets in the absence of clinical
information, meaning all 22 PROMPT criteria have been ap-
plied to the datasets in the North and Republic of Ireland [8].
To our knowledge, this is the first study to determine the
prevalence of PIP in middle-aged people. This study demon-
strated that the PROMPT criteria are applicable to prescribing
in two different health systems. The use of data from the EPD
in this study is representative of the entire middle-aged popu-
lation of Northern Ireland. Conversely, the use of data from
the HSE-PCRS GMS scheme represents the most socio-
economically deprived third of the middle-aged population
of Republic of Ireland. Therefore, the populations in these
datasets are not directly comparable. However, this work pro-
vides an opportunity to explore how PIP prevalence varies
across two similar populations with different healthcare sys-
tems and socio-economic profiles. Operational differences be-
tween the two datasets used may also have contributed to
contrasting prevalence estimates. Medications were classified
according to two different systems (BNF and ATC) necessi-
tating a change in coding to ensure comparable analysis of
PIP. This may also lead to differences in polypharmacy rates,
as BNF categories and the first five characters of ATC codes
were used to distinguish drug classes in the EPD and HSE-
PCRS database respectively. Differences in medicines used in
each jurisdiction may have affected prevalence estimates, for
example only one stimulant laxative is available on the HSE-
PCRS GMS scheme and hence no cases of this duplication
were found.
There are some limitations associated with the use of large
dispensing datasets for observational studies. Firstly, in the
EPD dataset, approximately 85–90 % of all prescriptions
forwarded to the BSO are added to the EPD database [14].
Therefore, a small proportion of prescriptions dispensed by
community pharmacies in Northern Ireland will not be collat-
ed in this database. Secondly, although this study is only con-
cerned with medications prescribed by a GP, lack of available
information on over-the-countermedication use in the datasets
could affect the accuracy of prevalence estimates. For exam-
ple, PIP may be overestimated if a patient on a strong opioid
has purchased an over-the-counter laxative, or alternatively
may be underestimated if a patient is taking over-the-counter
omeprazole while on clopidogrel. Although both of the
datasets used longitudinal records of dispensed medications,
which eliminates the issue of primary non-adherence to ther-
apies which can occur when prescribing datasets are used, it is
still not possible to determine whether patients take (adhere to)
medications that have been dispensed. Thirdly, application of
the PROMPT criteria to these datasets required a number of
assumptions, such as: nitrofurantoin was being prescribed in
all cases for uncomplicated lower urinary tract infections, and
alpha adrenoreceptor blockers were being prescribed for hy-
pertension only. Finally, as described in the methods, clinical
circumstances such as disease diagnosis and duration of
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medication prescription had to be operationalised for analysis
using information included in these large dispensing datasets.
Although less accurate than if full patient medical notes with
diagnoses had been available, these approaches were consis-
tent with similar administrative database studies [31].
Conclusion
This study has shown that PIP is prevalent in middle-aged
people, a population which was previously under-researched.
Further studies investigating healthcare outcomes (such as
hospital admissions, medication-related problems) may help
inform interventions to improve prescribing practices in this
age group, particularly in the most socio-economically de-
prived populations where the risk of PIP is greatest.
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